Wednesday, 20 January 2021

China NMPA approves CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy for thalassemia

China NMPA approves CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy for thalassemia admin Wed, 01/20/2021 - 16:05

source https://www.pharmatutor.org/pharma-news/2021/china-nmpa-approves-crispr-cas-9-gene-editing-hematopoietic-stem-cell-therapy-for-thalassemia

No comments:

Post a Comment

Pharmaceutical jobs for MPharm / MSc / BPharm or BSc - DPharm or PharmD and PhD

  Openings for Pharmacists under the National Health Mission Degree or Diploma in Pharmacy (50%) & Registration in CG Pharmacy Registrat...